Are you overpaying for your weight loss medication?

Wegovy costs approximately £149 to £400 per month in the UK depending on provider and dosage tier. At the 2.4mg maintenance dose, major UK providers charge £199 to £349 per month on a subscription basis. Most providers operate on a subscription model that includes the drug, clinical consultation, and delivery. Prices have generally fallen over the past 18 months as competition among online pharmacy and telehealth providers has increased. The NHS provides Wegovy at the standard prescription charge of £9.90 per item in England (free in Scotland, Wales, and Northern Ireland), but eligibility is restricted to BMI 35 or above with at least one weight-related health condition, managed through specialist weight management clinics. (Source: NHS England; NICE TA1003, 2025.)

Yes, Wegovy is available on the NHS in England at the standard £9.90 prescription charge, following NICE approval in 2023 (Technology Appraisal TA1003). Access is restricted to a BMI of 35 or above with a comorbidity such as type 2 diabetes, high blood pressure, or high cholesterol (or BMI 30 or above for patients from certain ethnic groups), managed through specialist weight management clinics. In Scotland, NICE recommendations are implemented by the Scottish Medicines Consortium, with similar criteria. Wales and Northern Ireland have their own approval processes. Waiting times for NHS weight management clinics can be substantial. Private prescriptions from online providers offer faster access but at a higher cost. (Source: NICE TA1003, March 2023.)

The cheapest Wegovy in the UK is via NHS prescription at £9.90 per item in England (free in Scotland, Wales, and Northern Ireland), if you qualify. For private prescriptions, prices start from around £149 per month, and comparing across providers can save £50 to £150 per month at the same dosage. NHS access requires BMI 35 or above with a weight-related health condition and a referral to a specialist weight management clinic. For those who prefer private treatment, comparing quotes across Boots Online Doctor, LloydsPharmacy, Asda Online Doctor, MedExpress, Numan, Voy, Superdrug, and Pharmacy2U is worthwhile. Some providers offer subscription plans at lower monthly rates than single-purchase pricing. It is also worth checking whether any provider is currently running a starter promotion, as many have historically offered discounted first-month pricing. (Source: provider pricing pages; NHS England prescription charge schedules.)

Ozempic costs approximately $750 to $935 per month without insurance in the US, depending on pharmacy. Costco and Sam's Club typically offer the lowest cash prices at 20 to 30% below the national average. The list price (wholesale acquisition cost) for the 1mg pen is approximately $935 per month, but GoodRx cash prices at most pharmacies are typically $750 to $900. Amazon Pharmacy has also offered competitive cash pricing. Novo Nordisk's savings programme, NovoCare, provides assistance for patients who qualify, and some income-qualified patients can access the medication for free or at reduced cost through the manufacturer's patient assistance programme. Compounded semaglutide from telehealth platforms was available at $150 to $400 per month during the shortage period, but FDA restrictions on compounding have reduced availability since late 2024. (Source: GoodRx; Novo Nordisk NovoCare; FDA compounding guidance, 2024.)

Mounjaro and Wegovy are broadly similar in price in the UK private market, with Mounjaro sometimes marginally cheaper. However, Mounjaro produces greater average weight loss (20 to 25% vs 15 to 17%), making it more cost-effective per kg lost. Clinical trial data shows Mounjaro produces average weight loss of 20 to 25% of starting body weight (SURMOUNT-1, Jastreboff et al., NEJM 2022), compared to 15 to 17% for Wegovy (STEP-1, Wilding et al., NEJM 2021). At the same monthly price, Mounjaro delivers meaningfully greater expected weight loss for most people. Individual responses vary, and efficacy data reflects average clinical trial outcomes rather than guaranteed personal results. (Source: Wilding et al. NEJM 2021; Jastreboff et al. NEJM 2022.)

Compounded semaglutide is manufactured by compounding pharmacies at lower cost than branded Wegovy or Ozempic, typically $150 to $400 per month in the US. In the UK, compounded semaglutide is not legally available, as MHRA regulations are more restrictive than those in the US. In the United States, compounded semaglutide was widely available during the shortage period from 2022 to 2024. The FDA allowed compounding during the shortage but began restricting it as supply improved in 2024 and 2025. In the United Kingdom, the MHRA has not authorised compounded semaglutide products. Patients seeking lower-cost semaglutide in the UK are therefore limited to branded Wegovy or, for those with type 2 diabetes, Ozempic via a GP prescription. (Source: MHRA; FDA compounding guidance, 2024.)

Medicare Part D does not cover Wegovy or other GLP-1 medications prescribed for weight loss, though Ozempic is covered when prescribed for type 2 diabetes. Without coverage, patients pay $750 to $935 per month cash price for Ozempic; cash prices across pharmacies can differ by $100 to $200 per month for the same medication. This exclusion dates from the 1990s when Congress explicitly barred Medicare coverage for weight loss drugs. Several legislative proposals to change Medicare's exclusion of anti-obesity medications have advanced in recent congressional sessions, including the Treat and Reduce Obesity Act, but none has passed as of 2025. For a broader picture of health cost data across the US population, see the health statistics roundup. (Source: CMS; KFF Health Benefits Survey 2024.)

The Novo Nordisk WeGoTogether savings card reduces Wegovy costs to as low as $25 per month for commercially insured patients. Eli Lilly's Zepbound savings card offers similar reductions for Zepbound for commercially insured patients. These programmes are available only to patients with commercial insurance, not Medicare or Medicaid. Ozempic has a similar NovoCare savings programme. Eligibility requirements include income thresholds in some cases. The cards are applied at the pharmacy counter and can be requested through the manufacturer's website or via the prescribing provider. Availability and terms change periodically, so it is worth checking the most recent terms directly on the Novo Nordisk or Eli Lilly websites before your next refill. (Source: Novo Nordisk WeGoTogether; Eli Lilly Zepbound Savings.)

Wegovy produces average weight loss of 15 to 17% of body weight over 68 weeks; Mounjaro produces 20 to 25% over 72 weeks in clinical trials. These are population averages from large randomised controlled trials (Wegovy: STEP-1, N=1961; Mounjaro: SURMOUNT-1, N=2539). A significant minority of patients achieve greater results (so-called super responders), while others see more modest reductions. About 10 to 15% of trial participants did not achieve clinically meaningful weight loss. Results also depend on adherence to the titration schedule and whether dietary and lifestyle changes accompany medication. Individual outcomes vary significantly from trial averages. (Source: Wilding et al. NEJM 2021;384:989. Jastreboff et al. NEJM 2022;387:205.)

Most patients regain two-thirds of their lost weight within 12 months of stopping GLP-1 treatment, based on the STEP-1 extension trial. Weight management therefore typically requires ongoing medication, representing a long-term cost commitment. The STEP-1 extension trial (Wilding et al., Diabetes, Obesity and Metabolism, 2022) showed participants who discontinued semaglutide regained two-thirds of their lost weight within a year, with metabolic improvements also partially reversing. This indicates GLP-1 medications address the physiology of obesity rather than its root causes. At £200 to £300 per month for a private UK prescription, indefinite use represents a £2,400 to £3,600 annual cost. The annual cost section of this calculator shows your projected 12-month spend and potential savings from switching provider. (Source: Wilding et al. Diabetes Obes Metab. 2022;24:1553.)

Private weight loss medication costs £2,400 to £4,800 per year in the UK, which compares favourably to the NHS cost of untreated obesity-related conditions. Type 2 diabetes management costs the NHS approximately £2,700 per patient per year, and knee replacement surgery for obesity-related osteoarthritis costs £9,000 to £15,000. Cardiovascular treatment costs are also substantially higher in people with obesity. Against these benchmarks, private prescription costs of £2,400 to £4,800 per year look more defensible for patients at high metabolic risk. For those at lower health risk seeking primarily cosmetic weight loss, the value calculation is more personal. The health statistics for the UK and US population, including obesity prevalence and comorbidity rates, are summarised on the health statistics page. (Source: NHS England cost-effectiveness data; NICE TA1003.)

Yes, weight loss drug prices are expected to fall, with UK private market prices already down since 2023 and biosimilar semaglutide potentially arriving within 3 to 5 years of patent expiry. In the US, biosimilar entrants in similar drug categories have historically reduced prices by 50 to 80% within five years of launch. In the UK, increased competition among private prescription providers has already driven prices lower since 2023. In the US, GoodRx cash prices have fallen modestly as pharmacy competition has intensified. Semaglutide's core patents begin expiring in several jurisdictions from 2026 onwards, which could allow biosimilar manufacturers to enter the market. However, biologics like semaglutide are more complex than small-molecule drugs, and regulatory hurdles for biosimilar approval are higher. NICE is also in negotiations with Novo Nordisk on an NHS-wide rebated price that could reduce effective public-sector costs substantially. (Source: Office of the US Patents and Trademark Office; NHS England commercial negotiations guidance.)